GABA A Application of receptors as targets in the preparation or screening of drugs for lowering blood lipids, treating obesity and / or improving metabolism
By targeting GABAA receptors, especially GABAA receptors in the dorsal nucleus of the vagus nerve, inhibiting the absorption of oil in the small intestine, the shortcomings of existing obesity treatment methods are solved, and the effects of lowering blood lipids and improving metabolism are achieved.
Patent Information
- Application Number
- CN202211464037.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-22
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-11-22
AI Technical Summary
The existing obesity treatment methods are relatively limited, and it is difficult to effectively reduce blood lipids and improve metabolic syndrome, and there is a lack of safe and effective drug targets.
Using GABAA receptors as targets, by enhancing their expression levels, increasing sensitivity, or using agonists and allosteric agents such as puerarin, it inhibits the nerve excitability of the dorsal nucleus of the vagus nerve, thereby reducing small intestinal oil absorption and lowering blood lipids and body weight.
Effectively inhibit the absorption of small intestine oil, reduce blood lipid levels, reduce weight, and improve metabolic syndrome, providing new drug targets and treatment methods for obesity treatment and blood lipid reduction.
Smart Images

Figure CN116115758B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to GABA A GABA receptor A Receptor) as a target in the preparation or screening of drugs for lowering blood lipids, treating obesity and / or improving metabolism. Background Art
[0002] Obesity is a risk factor for many diseases such as diabetes, cardiovascular disease, and cancer, which seriously endangers human health. With the improvement of living conditions and the change in people's dietary structure, the number of obese people in the world has increased rapidly. In 2021, the international journal "The Lancet Diabetes & Endocrionology" published a special issue on "China's Obesity Problem", reporting that the obesity prevalence rate among adults in my country has reached 16.4%, and the overweight rate has reached 34.3%, making China the country with the largest obese population in the world. 1-4 However, the current means of treating obesity and effectively reducing weight are relatively limited. Therefore, in order to improve the quality of life of the people, enhance health status, and prevent chronic diseases, it is urgent to explore new strategies for obesity treatment and develop safer and more effective obesity intervention methods.
[0003] References:
[0004] 1Pan,
[0005] 2Zeng, Q., Li, N., Pan,
[0006] 3Collaboration,NCDRFTrends in adultbody-mass index in 200countries from 1975to 2014:a pooled analysis of 1698population-basedmeasurement studies with 19.2million participants.Lancet 387,1377-1396,doi:10.1016 / S0140-6736(16)30054-X(2016).
[0007] 4Lu, J., Bi, Y. & Ning, G. Curbing the obesity epidemic in China. LancetDiabetes Endocrinol4, 470-471, doi:10.1016 / S2213-8587(16)30007-9(2016). Summary of the invention
[0008] The present invention aims to provide GABA A The use of GABA receptors as targets in the preparation or screening of drugs for lowering blood lipids, treating obesity and / or improving metabolism. A The receptor is closely related to the small intestine's fat absorption capacity. The application of the present invention provides a new drug target and a new treatment method for obesity treatment, lowering blood lipids, and improving metabolism.
[0009] The present invention provides GABA A The use of receptors as targets in the preparation or screening of drugs having any one or more of the effects shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption.
[0010] The present invention also provides a method for enhancing GABA A The use of a substance that regulates the expression level of a receptor in the preparation of a drug having any one or more of the effects as shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption.
[0011] The present invention also provides a method for increasing GABA A The use of substances that increase the sensitivity of receptors or the frequency of chloride channel opening or increase chloride ion influx or cause nerve cell hyperpolarization in the preparation of drugs having any one or more of the effects as shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption.
[0012] The present invention also provides GABA A The use of receptor agonists and / or allosteric agents in the preparation of drugs having any one or more of the effects as shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption.
[0013] Preferably, the GABA A Receptor agonists include puerarin and / or puerarin derivatives, or benzodiazepines Benzodiazepines This type of drug includes one or more of flunitrazepam, diazepam, triazolam and flumazenil.
[0014] The present invention also provides the use of a substance that inhibits the neural excitability of the dorsal nucleus of the vagus nerve (DMV) in the preparation of a drug having any one or more of the effects shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption.
[0015] Preferably, the substance that inhibits the excitability of the dorsal nucleus of the vagus nerve includes a substance that enhances GABA A Substances that increase the expression level of GABA receptors A The sensitivity of the receptor or the frequency of chloride channel opening or substances that increase chloride ion influx or cause neuronal hyperpolarization.
[0016] The present invention also provides the use of puerarin and / or puerarin derivatives in the preparation of drugs having any one or more of the effects as shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption.
[0017] The present invention also provides the use of gene Gabra1 and / or gene Gabrg2 as drug targets in screening drugs having any one or more of the effects shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption.
[0018] The present invention provides GABA A The use of receptors as targets in the preparation or screening of drugs for lowering blood lipids, treating obesity and / or improving metabolism. A The receptor has the effects of inhibiting intestinal fat absorption, lowering blood lipids, treating obesity and improving metabolism. A The receptor can be used as a drug target for obesity treatment, lowering blood lipids, inhibiting small intestinal fat absorption and improving metabolism. The present invention provides GABA in the dorsal nucleus of the vagus nerve AThe application of puerarin (and its derivatives) as a drug target in lipid-lowering, weight-reducing and metabolism-improving drugs; the research results of the present invention show that puerarin (and its derivatives) is a GABA A Agonists and allosteric agents of GABA receptors, puerarin (and its derivatives) A The receptors can inhibit the excitability of the dorsal nucleus of the vagus nerve, resulting in the inhibition of the small intestine's ability to absorb fat, thereby lowering blood lipids, reducing weight (treating obesity) and improving metabolism, providing experimental data and theoretical basis for the development of weight-loss drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.
[0020] Figure 1 The chemical genetics strategy provided by the present invention demonstrates the regulatory effect of the dorsal nucleus of the vagus nerve on the small intestinal fat absorption; wherein A is an experimental flow chart of the chemical genetics strategy for inhibiting the dorsal nucleus of the vagus nerve (DMV) neurons; B is a weight curve record of the experimental group and the control group after the chemical genetics strategy inhibits the DMV neurons; C is a result chart of the change in blood lipid level after the dorsal nucleus of the vagus nerve (DMV) is inhibited; D is a result chart of fecal triglyceride excretion before and after the chemical genetics strategy intervention; E is a result chart of the chemical genetics strategy inhibiting the absorption of triglyceride and other lipid nutrients in the jejunum of the DMV;
[0021] Figure 2 The present invention provides a brain slice electrophysiological recording result diagram of the inhibitory effect of puerarin on neurons of the dorsal nucleus of the vagus nerve; wherein A is a brain slice electrophysiological operation display diagram (the electrode liquid of the recording electrode contains a green fluorescent dye to mark the recorded neuronal cells); B is a brain slice electrophysiological result diagram (recording the action potential of DMV neurons during the incubation period and after the washout of puerarin),
[0022] Figure 3The results of the invention show that puerarin can inhibit the absorption of fat in the small intestine and reduce body weight in the obese mouse model; wherein A is a schematic diagram of the process of intraperitoneal injection of puerarin into the obese mouse model; B is a result diagram of cfos immunofluorescence staining of brain slices, wherein the fluorescent signal represents neuronal activity; C is a result diagram of the weight curve recording of the obese mouse model in the puerarin experimental group and the control group; D is a result diagram of the quantitative determination of blood lipid levels in the puerarin experimental group and the control group; E is a result diagram of the determination of triglycerides absorbed in the jejunum in the puerarin experimental group and the control group; F is a representative diagram of oil red staining, which intuitively presents the absorption of lipid nutrition in the small intestine;
[0023] Figure 4 The puerarin and GABA provided by the present invention A The co-localization staining results of receptors in the dorsal nucleus of the vagus nerve;
[0024] Figure 5 The puerarin and GABA provided by the present invention A Cryo-electron microscopy analysis of the drug binding site of the receptor; A is puerarin and GABA A (α1β3γ2) receptor binding cryo-electron microscopy structure display; B is the result of the electrical signal change;
[0025] Figure 6 The specific knockdown of Gabra1 provided by the present invention can block the inhibitory effect of puerarin on DMV neurons and the effects of weight loss, lowering blood lipids, improving metabolism, etc.; wherein A is a schematic diagram of the process of intraperitoneal injection of puerarin in a DMV-specific knockdown of Gabra1 obese mouse model; B is a diagram of the results of brain slice cfos immunofluorescence staining; C is a diagram of the quantitative statistical results of the cfos staining signal of the DMV nucleus; D is a diagram of the weight curve recording results of the obese mouse model of the control group, puerarin group and Gα blocking group; E is a diagram of the quantitative determination of blood lipid levels in the control group, puerarin group and Gα blocking group; F is a diagram of the determination of triglycerides absorbed in the jejunum in the control group, puerarin group and Gα blocking group;
[0026] Figure 7 The specific knockdown of Gabrg2 provided by the present invention can block the inhibitory effect of puerarin on DMV neurons and the effects of weight loss, lowering blood lipids, improving metabolism, etc.; wherein A is a schematic diagram of the process of intraperitoneal injection of puerarin in a DMV-specific knockdown of Gabrg2 obese mouse model; B is a result diagram of cfos immunofluorescence staining of brain slices; C is a quantitative statistical diagram of cfos staining signals of DMV nuclei; D is a result diagram of the weight curve recording of the obese mouse model of the control group, puerarin group and Gγ2 blocking group; E is a result diagram of the quantitative determination of blood lipid levels in the control group, puerarin group and Gγ2 blocking group; F is a result diagram of the determination of triglycerides absorbed in the jejunum in the control group, puerarin group and Gγ2 blocking group;
[0027] Figure 8 The invention provides a result diagram of the inhibition of small intestinal fat absorption, reduction of blood lipids and weight loss by the puerarin derivatives provided by the present invention; wherein A is the chemical structural formula of puerarin derivative-1; B is a result diagram of the weight curve of the obese mouse model of the control group and the derivative-1 group; C is a result diagram of the quantitative determination of blood lipid levels of the control group and the derivative-1 group; D is a result diagram of the determination of triglycerides absorbed in the jejunum of the control group and the derivative-1 group; E is the chemical structural formula of puerarin derivative-2; F is a result diagram of the weight curve of the obese mouse model of the control group and the derivative-2 group; G is a result diagram of the quantitative determination of blood lipid levels of the control group and the derivative-2 group; H is a result diagram of the determination of triglycerides absorbed in the jejunum of the control group and the derivative-2 group; I is the chemical structural formula of puerarin derivative-3; J is a result diagram of the weight curve of the obese mouse model of the control group and the derivative-3 group; K is a result diagram of the quantitative determination of blood lipid levels of the control group and the derivative-3 group; and L is a result diagram of the determination of triglycerides absorbed in the jejunum of the control group and the derivative-3 group. DETAILED DESCRIPTION
[0028] The present invention provides GABA A The use of receptors as drug targets in screening drugs with any one or more of the effects shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption. GABA A The receptor is a chloride ion channel receptor in nerve cells. Under physiological conditions, GABA A The receptor binds to γ-aminobutyric acid (GABA), prompting the opening of chloride ion channels, which leads to a hyperpolarized state of nerve cells and inhibits the excitability of cell cells.
[0029] The present invention also provides a method for enhancing GABA A The use of a substance that regulates the expression level of a receptor in the preparation of a drug having any one or more of the effects as shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption.
[0030] The present invention also provides a method for increasing GABA A The use of substances that increase the sensitivity of receptors or the frequency of chloride channel opening or increase chloride ion influx or cause nerve cell hyperpolarization in the preparation of drugs having any one or more of the effects as shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption.
[0031] The present invention also provides GABA A GABA receptor agonists (targeting the dorsal nucleus of the vagus nerve in the brainstem AThe use of agonists of GABA receptors and / or allosteric agents in the preparation of drugs having any one or more of the effects as shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting intestinal fat absorption. Using cryo-electron microscopy technology, it was found that puerarin acts on GABA A The site between the α1 and γ2 subunits of the receptor, where puerarin can bind to GABA A Receptor binding promotes the opening of chloride ion channels and significantly increases the inhibitory effect of γ-aminobutyric acid on neurons. Puerarin is a GABA receptor in the dorsal nucleus of the vagus nerve. A Receptor agonists.
[0032] In the present invention, the GABA A Receptor agonists include puerarin and / or puerarin derivatives, or benzodiazepines Benzodiazepines This type of drug includes one or more of flunitrazepam, diazepam, triazolam and flumazenil.
[0033] The present invention also provides the use of a substance that inhibits the excitability of the dorsal nucleus of the vagus nerve in the preparation of a drug having any one or more of the effects shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption. The dorsal nucleus of the vagus nerve (DMV) in the mammalian brainstem controls visceral movement and regulates digestion and absorption. GABA A The receptors are highly expressed in DMV. Previous studies have shown that GABA A GABA receptors can be used as drug targets for sedation, anxiolysis, anticonvulsant, and depression relief; GABA receptors in the dorsal nucleus of the vagus nerve A The application of receptors as drug targets for treating obesity, lowering blood lipids, improving metabolism and inhibiting small intestinal fat absorption is disclosed for the first time in the present invention. The present invention inhibits the excitability of the dorsal nucleus of the vagus nerve (DMV) of mice by chemical genetics, analyzes their body weight curve, blood lipids, small intestinal absorption and other metabolic indicators, and finds that inhibiting DMV excitability can inhibit small intestinal fat absorption.
[0034] In the present invention, the substance that inhibits the excitability of the dorsal nucleus of the vagus nerve includes a substance that enhances GABA A Substances that increase the expression level of GABA receptors A The sensitivity of the receptor or the frequency of chloride channel opening or substances that increase chloride ion influx or cause neuronal hyperpolarization.
[0035] The present invention also provides the use of puerarin and / or puerarin derivatives in the preparation of drugs having any one or more of the effects shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption. Puerarin is a class of isoflavone compounds and is the main active ingredient of the traditional Chinese medicine Pueraria root. Its molecular formula is shown in Formula I:
[0036]
[0037] Through electrophysiological analysis of brain slices, the present invention found that puerarin (and its derivatives) can activate GABA through the "DMV nucleus A GABA receptors - vagus nerve - small intestinal nutrient absorption A The receptors are highly expressed in the DMV nuclei; in normal physiological state, the endogenous neurotransmitter γ-aminobutyric acid and GABA A Receptor binding, inhibiting neuronal excitability, puerarin and GABA A After receptor binding, it can amplify GABA A The receptors respond to γ-aminobutyric acid, that is, when receiving a small amount of γ-aminobutyric acid, there is the effect of puerarin, and the dorsal nucleus of the vagus nerve can produce a stronger inhibitory effect on the small intestine) inhibits the excitability of the dorsal nucleus of the vagus nerve (DMV) and inhibits the absorption of fat by the small intestine. Animal studies have shown that puerarin (and its derivatives) can inhibit the absorption of lipid nutrients by the small intestine through the vagus nerve, promote the excretion of unabsorbed fat through feces, and achieve the effect of lowering blood lipids, reducing weight, and treating obesity.
[0038] Using puerarin probe, it was demonstrated that puerarin is enriched and bound to the DMV nucleus of the vagus nerve and binds to brainstem GABA A The receptors showed co-localization staining; at the same time, with the help of cryo-electron microscopy CryoEM technology, the present invention found that puerarin acts on brainstem GABA A Drug targets for receptors that bind to GABA A The site between the α1 and γ2 subunits of the receptor inhibits the excitability of the dorsal nucleus of the vagus nerve by regulating chloride ion channels (i.e., puerarin can bind to GABA A Receptor binding, promoting the opening of chloride ion channels, and significantly increasing the inhibitory effect of GABA on neurons).
[0039] The present invention also provides the use of gene Gabra1 and / or gene Gabrg2 as drug targets in screening drugs having any one or more of the effects shown in ① to ④: ① lowering blood lipids; ② treating obesity; ③ improving metabolic syndrome; ④ inhibiting small intestinal fat absorption. A receptor α1 subunit) or Gabrg2 (GABA Areceptor γ2 subunit gene), proving that puerarin is expressed through GABA A The receptors play a role in inhibiting the absorption of fat in the small intestine. Specifically, the present invention uses Gabra1 shRNA virus (rAAV-DIO-Gabra1-shRNA, BrainVTA, China) to specifically knock down GABA in the dorsal nucleus of the vagus nerve. A Expression of receptor α1 subunit, demonstrated in an obese mouse model of GABA A The receptors in puerarin inhibit small intestinal fat absorption, lower blood lipids, and reduce weight, explaining the "DMV nucleus-GABA A Similarly, the present invention also demonstrated that DMV tissue-specific knockdown of Gabrg2 can block the inhibitory effect of puerarin on the vagus nerve, interfere with its effects of inhibiting small intestinal fat absorption, reducing weight, and lowering lipids through the Gabrg2 shRNA virus rAAV-DIO-Gabrg2-shRNA (BrainVTA, China).
[0040] In order to further illustrate the present invention, the following is a GABA provided by the present invention in conjunction with the accompanying drawings and embodiments. A The use of receptors as drug targets in screening drugs for lowering blood lipids, treating obesity and / or improving metabolism is described in detail, but they should not be construed as limiting the scope of protection of the present invention.
[0041] Example 1
[0042] 1. Establishment and testing of experimental animal models
[0043] (1) Establishment of animal model of obesity
[0044] The C57BL / 6J strain mice used in the present invention were all raised in an SPF environment with a 12:12 circadian rhythm and a temperature of 22-24°C. The experimental animals were subjected to anesthesia, analgesia, surgery, intraperitoneal injection and other experimental operations in accordance with relevant animal ethics regulations.
[0045] The present invention feeds mice with a high-fat diet containing 60% fat by weight for 12 weeks, and the weight reaches more than 35g, thus constructing an animal model of dietary obesity. Figure 1 , Figure 3 , Figure 6 and Figure 7 Starting from day 0 in A in FIG), mice were housed in individual cages, the daily food intake of each mouse model was accurately recorded, feces were collected before and after drug intervention, and daily body weight curves were recorded.
[0046] (2) Chemical genetic virus injection
[0047] Chemical genetics (Designer Receptors Exclusively Activated by Designer Drugs, DREADDs) is a research method for controlling the excitability of neurons in specific brain regions in animal models. It activates the downstream signaling pathway of the specific exogenous ligand clozapine N-oxide (CNO) through the AAV virus modified by G protein-coupled receptors, causing changes in neuronal excitability. The present invention uses the dorsal nucleus of the vagus nerve as the entry point, and constructs a mouse model for intervening the dorsal nucleus of the vagus nerve with the help of an inhibitory chemical genetic virus (rAAV-Ef1a-DIO-hM4D(Gi)-mCherry-WPRE-pA, purchased from Shumi Brain Science and Technology Co., Ltd., BrainVTA, China) and its control virus (rAAV-Ef1a-DIO-mCherry-WPRE-pA, purchased from Shumi Brain Science and Technology Co., Ltd., BrainVTA, China). The specific experimental operations are as follows:
[0048] The mice were deeply anesthetized with sodium pentobarbital and fixed on a stereotaxic apparatus. The skin was opened to expose the cranial face. The dorsal nucleus of the vagus nerve (DMV coordinates: -7.10mm, ±0.2mm, -4.50mm) was located according to the Bregma point. A cranial drill was used to drill holes. 300nL of virus was injected on each side with a microinjector for 5 minutes and stabilized for 5 minutes. After the injection, chlortetracycline ointment was applied to the cranial face for anti-inflammatory treatment. The wound was then sutured and placed on a 37°C hot pad for 1 hour to recover. The mice were then returned to the cage and waited for them to wake up. The chemical genetic inhibition group and the control group were injected with two viruses, the inhibitory chemical genetic virus (rAAV-Ef1a-DIO-hM4D(Gi)-mCherry-WPRE-pA, BrainVTA, China) and the control virus (rAAV-Ef1a-DIO-mCherry-WPRE-pA, BrainVTA, China) in the DMV nucleus, and the other operations were completely the same.
[0049] After four weeks of recovery from surgery, the mice in the chemical genetic inhibition group and the control group were intraperitoneally injected with clozapine N-oxide (CNO, catalog No. BML-NS105, Enzo Life Sciences, USA) at a dose of 1.0 mg / kg BW every day to inhibit the neural activity of the dorsal nucleus of the vagus nerve, and the daily food intake and body weight of the mice were observed, and feces were collected. After 7 days of continuous inhibition of the dorsal nucleus of the vagus nerve by CNO injection, the mice were sacrificed, and the mouse tissue samples were collected, and physiological metabolic indicators were detected and analyzed.
[0050] 2. Detection and analysis of physiological and metabolic indicators
[0051] The physiological metabolic indicators involved in the present invention include: the content of triglycerides (TG) and free fatty acids (NEFA) in samples such as plasma, intestinal tissue and feces.
[0052] The method for determining triglycerides (TG) in samples is as follows: First, weigh 20-30 mg of the sample, add lysis solution containing 5% NP40, homogenize, and add in a metal bath at 95°C for 5 minutes, repeat twice; after cooling to room temperature, centrifuge at 15,000 rpm for 2-3 minutes, and aspirate the supernatant for determination. Use the Biovision kit to determine triglycerides, add 2 μl of the above sample supernatant to each well, and after color development, measure the value by an enzyme marker. The triglycerides in the small intestinal tissue are quantified using the standard protein concentration; the total amount of lipids excreted with the feces is obtained by calculating the measured value and the total mass of the 24h sample for fecal samples.
[0053] The free fatty acids (NEFA) in the samples were extracted by isopropanol / chloroform / Triton-100 extraction, dried in an oven at 50°C, and vacuum treated with a vacuum pump for 30 minutes, and then dissolved in a 5% NP-40 solution. Subsequently, the difference in the quantification of the Wako kit (catalog No. 294-63601, WAKO, Japan) before and after the addition of the sample was compared to quantify the NEFA in the sample.
[0054] Based on the above-mentioned physiological index detection and analysis implementation methods, the present invention mainly detects physiological indexes related to lipid metabolism such as weight curve, fecal fat, intestinal fat, and blood lipids of animal models.
[0055] Figure 1 The results of chemical genetics strategy to demonstrate the regulatory effect of dorsal nucleus of vagus nerve on small intestinal lipid absorption. Figure 1 A in the figure is the experimental flow chart of the chemical genetic strategy: 8-week-old male mice were used to construct a diet-induced obesity mouse model. After being fed with a high-fat diet for 8 weeks, the mice were randomly divided into two groups. The inhibitory chemical genetic virus and its control virus were injected into the dorsal nucleus DMV of the vagus nerve of the mice, respectively, to construct two animal models of the inhibition group and the control group. After continuing the high-fat diet for 4 weeks, the body weight reached more than 35g, and the body weight and fecal samples were collected as the initial baseline, which was counted as "Day 0"; from the first day, CNO was injected intraperitoneally to activate the DMV nucleus through a chemical genetic strategy. CNO was injected once a day for 7 days, and daily weight changes were recorded. The mice were sacrificed 2 hours after the injection of CNO on the 7th day, and blood, feces, small intestine and other tissues were collected to quantitatively measure the lipid components in each sample to obtain Figure 1 B- Figure 1 Experimental results in E.
[0056] After chemical genetics inhibition of DMV neurons in the dorsal nucleus of the vagus nerve (i.e., intraperitoneal injection of CNO), the weight of obese mice in the inhibition group gradually decreased. After 7 days of inhibition of DMV neurons, the weight of obese mice in the inhibition group was significantly lower than that of the control group ( Figure 1 B in Table 1), blood lipid levels were significantly reduced ( Figure 1 C in Table 2). Figure 1 As shown in D and Table 3, before and after the intervention of the chemical genetics strategy (i.e., before injection of CNO and 7 days after injection of CNO), a large amount of unabsorbed triglycerides in the inhibition group can be excreted from the body through feces; the chemical genetics strategy inhibits DMV, and the triglycerides and other lipid nutrients absorbed into the small intestine through the jejunal segment are significantly reduced ( Figure 1 The above experimental results show that the inhibition of the dorsal nucleus DMV of the vagus nerve can significantly reduce small intestinal fat absorption, lower blood lipids, and reduce body weight.
[0057] Table 1 Percentage change of body weight curve (%)
[0058]
[0059] Table 2 Blood lipid levels (mM)
[0060]
[0061] Table 3 Triglyceride excretion in feces (μmol)
[0062]
[0063] Table 4 Jejunal triglyceride levels
[0064]
[0065] The results of puerarin on the inhibition of small intestinal lipid absorption and weight loss in obese mice are as follows Figure 3 As shown, the present invention also clarifies the improvement effect of puerarin on physiological indicators related to lipid metabolism, such as body weight curve, fecal fat, intestinal fat, and blood lipids of obese mice through the above physiological indicator detection and analysis. Figure 3A in the figure is a schematic diagram of the process of intraperitoneal injection of puerarin in obese mouse models: As shown in the figure, 8-week-old male mice were taken and fed with high-fat diet for 12 weeks to make their body weight reach more than 35g. The above obese mouse model was randomly divided into two groups, and normal saline and puerarin solution were injected intraperitoneally respectively to construct the control group and puerarin group animal models. Before intraperitoneal injection of puerarin, fecal samples before intervention were collected, and body weight was recorded as the initial baseline, which was counted as "Day 0"; from the first day, normal saline and puerarin solution were injected intraperitoneally once a day for 20 days, and daily weight changes were recorded. The mice were sacrificed 2 hours after the injection of puerarin on the 20th day, and blood, feces, small intestine, brain and other tissues were collected. Physiological indicators such as blood lipids and jejunal triglycerides were quantitatively measured, and the morphological results of the dorsal nucleus of the vagus nerve in the brainstem and the small intestine were directly detected by tissue sections (including brain slice cfos immunofluorescence staining test and small intestinal oil red staining test).
[0066] Cfos immunofluorescence staining of brain slices Figure 3 As shown in B, the number of fluorescent signals represents the degree of neuronal excitability. It is a representative image of cfos staining of brain slices in the puerarin group and the control group. The number of cfos fluorescent signals in the DMV brain region (DMV nucleus of the dorsal nucleus of the vagus nerve) in the puerarin group is less than that in the control group, indicating that the neuronal excitability of the DMV dorsal nucleus of the vagus nerve is inhibited by puerarin. During the puerarin injection period, the weight curves of the puerarin experimental group and the control group were recorded ( Figure 3 C in Table 5), measuring blood lipids ( Figure 3 D in Table 6); and the jejunal lipid absorption capacity was detected by Biovision kit ( Figure 3 E in Table 7), such as Figure 3 F in the figure shows the representative picture of oil red staining of the puerarin group and the control group, which directly presents the total amount of lipids absorbed in the small intestine. The above experimental results show that puerarin can inhibit the excitability of DMV neurons in the dorsal nucleus of the vagus nerve, and the small intestine's fat absorption capacity is inhibited, blood lipids are reduced, and body weight gradually decreases with the injection of puerarin, which can achieve the effect of weight loss and lipid reduction.
[0067] Table 5 Percentage change of body weight curve (%)
[0068]
[0069] Table 6 Blood lipid levels (mM)
[0070]
[0071] Table 7 Jejunal triglyceride levels (μmol / mg / protein)
[0072]
[0073] 3. Brain slice electrophysiological experiments
[0074] After artificial cerebrospinal fluid (ACSF) was perfused into the heart of an obese mouse model that had been fed with high-fat for 12 weeks, 200-300 μm thick brainstem tissue slices were prepared by oscillating slices; after the brain slices were incubated with oxygen at 35°C for 1 hour, the brain slices were transferred to the patch clamp system for whole-cell patch clamp recording. Neurons to be recorded were selected in the dorsal nucleus of the vagus nerve based on cell morphology, and green fluorescent dye was added to the electrode liquid to mark the cells. The present invention continuously records the three stages of baseline, puerarin incubation and washout in current clamp mode to clarify the effect of drug treatment on DMV neurons: first, the spontaneous action potentials of neurons were recorded in the baseline part for 1-3 minutes; then, the spontaneous action potentials were continuously recorded and puerarin (10mM concentration) was started to be incubated, and the electrophysiological signals of the drug treatment stage of 5-30 minutes were recorded; finally, the ACSF washout process was recorded.
[0075] The results of brain slice electrophysiological recording of puerarin's inhibitory effect on neurons in the dorsal nucleus of the vagus nerve are shown in the figure below. Figure 2 shown.
[0076] Figure 2 A in the figure is a display of electrophysiological operation of brain slices of the dorsal nucleus of the vagus nerve in the brainstem. The electrode fluid of the recording electrode contains fluorescent dye (green) that can mark the neurons recorded by the electrode, indicating that Figure 2 The neurons recorded in A (labeled with green fluorescence) are neurons of the DMV nucleus.
[0077] like Figure 2 As shown in Figure B, the electrophysiological results of brain slices showed that the action potential firing frequency of neurons in the dorsal nucleus of the vagus nerve was significantly reduced during the incubation period of puerarin, and the membrane potential was slightly lower than the initial baseline. In summary, puerarin can inhibit the electrophysiological activity of neurons in the dorsal nucleus of the vagus nerve, inhibit the excitability of neurons, and inhibit the neurons in the DMV nucleus.
[0078] 4. Cryo-electron microscopy analysis of the drug binding site of puerarin and target receptors;
[0079] Referring to the relevant literature methods (Dai J, Liang K, Zhao S, et al. Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis. Proc Natl Acad Sci US A. 2018; 115(26): E5896-E5905), the interaction between puerarin and GABA was investigated in brain slices. A Immunofluorescence staining of puerarin and GABA receptorsA The results of co-localization staining of receptors in the dorsal nucleus of the vagus nerve are as follows Figure 4 shown. Figure 4 The puerarin probe was enriched in the dorsal nucleus of the vagus nerve (DMV) and colocalized with GABA A The staining of the receptors showed good colocalization, indicating that the target of puerarin may be GABA in the dorsal nucleus of the vagus nerve. A According to the expression profiles of various genes in the Allen Brain Atlas, an international database, GABA receptors composed of α1β3γ2 A The receptor (http: / / mouse.brain-map.org / gene / show / 14170) is enriched in the DMV nucleus and may be the molecular target of puerarin in the DMV nucleus.
[0080] According to the literature (Laverty, D. et al. Cryo-EM structure of the human alpha1beta3gamma2 GABAA receptor in a lipid bilayer. Nature 565, 516-520), the present invention constructs a GABAA receptor that is enriched and expressed in the dorsal nucleus of the vagus nerve. A Receptor pentamer form α1β3γ2GABA A The 293S stable cell line of the receptor, with the α1 subunit carrying a Flag tag, was used for protein purification to obtain a cell suspension of about 2L. After the cells were ultrasonically disrupted, the cell membrane was precipitated using an ultracentrifuge; after the cell membrane was dissolved with a detergent at 4°C for 2 hours, the membrane solution was obtained by high-speed centrifugation, and the membrane solution was incubated with anti-Flag resin to obtain GABA A The protein solution was concentrated to above 2 mg / mL and incubated with puerarin for 30 minutes to obtain GABA bound to puerarin. A Receptor protein samples.
[0081] Preparation of cryo-EM samples: prepare a glow-discharged porous carbon film copper grid, drop 3 μL of drug-receptor binding solution onto the surface of the copper grid, absorb the excess liquid and quickly place the copper grid in liquid ethane to freeze it to a glassy state, and store it in liquid nitrogen for cryo-EM acquisition.
[0082] The sample was collected using a 300kV FEI Titan Krios cryo-electron microscope to collect single-particle data, and a total of 142,931 single-particle protein images were obtained. The electron microscope images at each angle were clustered and grouped, the average 2D image at each angle was analyzed, Fourier operations were performed, and 3D models were reconstructed to obtain the final High-resolution cryo-electron microscopy images.
[0083] Figure 5 Analysis of cryo-electron microscopy: Puerarin and GABA A The drug binding site result diagram of the receptor. Among them, A is puerarin and GABA A (α1β3γ2) receptor binding cryo-EM structure display; here Resolution of GABA A In the receptor structure, puerarin and GABA A The drug binding site of the receptor at the atomic level, which is located at the GABA A The target sites of puerarin binding include the H 102 、V 203 -Q 204 -S 205 、T 207 , Y 210 and D of the γ2 subunit 56 -M 57 -Y 58 、N 60 、F 77 , A 79 Equivalent sites, which can be used as GABA A Receptors are the core drug targets for the preparation of obesity treatment drugs; B is that in the above 293S cell line, incubation with 0.5 μM GABA can cause GABA A (α1β3γ2) receptor opens chloride ion channels, producing changes in bioelectric signals ( Figure 5 B, left); if 0.5 μM GABA is co-incubated with puerarin for 3 to 5 minutes, more chloride ions will enter the cell, causing hyperpolarization and making the cell inhibited and silent ( Figure 5 B in the figure, right).
[0084] like Figure 5 As shown, cryo-electron microscopy analysis of puerarin and GABA A The drug binding site of the receptor at the atomic level, which is located at the GABA A The targets of puerarin binding include the H 102 、V 203 -Q 204 -S 205 、T 207 , Y 209 and D of the γ2 subunit 56 -M 57 -Y 58 、N 60 、F 77 , A 79Equivalent sites, which can be used as GABA A Receptors are core drug targets in the preparation of obesity treatment drugs.
[0085] like Figure 6 As shown, rAAV-DIO-Gabra1-shRNA (BrainVTA, China) was used to knock down Gabra1 (encoding GABA) in the dorsal nucleus of the vagus nerve in an obese mouse model (obtained by high-fat feeding for 12 weeks). A The gene of receptor α1 subunit) was used as the control group, and the viral vector rAAV-DIO-mCherry (BrainVTA, China) without the target gene was used as the control group.
[0086] Figure 6 A in the figure is a schematic diagram of the experimental process of specifically knocking down Gabra1 to block puerarin: as shown in the figure, 8-week-old male mice were used to construct a dietary obesity mouse model. After being fed with a high-fat diet for 8 weeks, the above obese mouse model was randomly divided into three groups: (1) DMV nucleus injection of control virus, followed by intraperitoneal injection of normal saline 4 weeks later, as the control group; (2) DMV nucleus injection of control virus, followed by intraperitoneal injection of puerarin solution 4 weeks later, as the puerarin group; (3) DMV nucleus injection of Gabra1 shRNA virus, followed by intraperitoneal injection of puerarin solution 4 weeks later, as the Gα1 blocking group; for the above three groups of animal models, body weight was recorded and fecal samples were collected before intraperitoneal injection of puerarin or normal saline as the initial baseline, and counted as "day 0". Starting from the first day, normal saline or puerarin solution was injected intraperitoneally once a day for 7 days, and the daily body weight changes were recorded. On the seventh day, the mice were sacrificed 2 hours after the injection of normal saline or puerarin, and blood, feces, small intestine, brain and other tissues were collected. Physiological indicators such as blood lipids and jejunal triglycerides were quantitatively measured, and the morphological results of the dorsal nucleus of the vagus nerve in the brainstem and the small intestine were directly detected by tissue sections.
[0087] Figure 6 The results of cfos immunofluorescence staining of brain slices in B showed that the cfos staining in the puerarin group was less than that in the control group, and DMV neurons were inhibited ( Figure 6 B, middle panel); while tissue-specific knockdown of Gabra1 (Gα1 blocking group, Figure 6 B, right) would interfere with the inhibitory effect of puerarin on DMV neurons; Figure 6 The quantitative statistics of the cfos staining signals in the above three groups are shown in Figure C and Table 8, which also show that the GABA A The receptor α1 subunit plays an essential role in the process of puerarin inhibiting neuronal excitability. The body weight curves, blood lipids and triglyceride levels absorbed by the jejunum were compared between the control group, puerarin group and Gα1 blocking group ( Figure 6 D in Figure 6 E (Table 9) and Figure 6 F in (Table 10), indicating that DMV tissue-specific knockdown of Gabra1 can block the inhibitory effect of puerarin on the vagus nerve, interfere with its inhibitory effect on small intestinal fat absorption, weight loss, and lipid reduction, indicating that GABA A The receptor α1 subunit is the target of puerarin in the treatment of obesity.
[0088] Table 8 Percentage change of body weight curve (%)
[0089]
[0090] Table 9 Blood lipid levels (mM)
[0091]
[0092] Table 10 Jejunal triglyceride levels (μmol / mg / protein)
[0093]
[0094] Similar to the above experiments, rAAV-DIO-Gabrg2-shRNA (BrainVTA, China) was used to knock down Gabrg2 (encoding GABA) in the dorsal nucleus of the vagus nerve in an obese mouse model. A receptor γ2 subunit gene), rAAV-DIO-mCherry (BrainVTA, China) as the control group, Figure 7 A in the figure is a schematic diagram of the experimental process of specifically knocking down Gabrg2 to block puerarin: 8-week-old male mice were used to construct a diet-induced obese mouse model. After being fed with a high-fat diet for 8 weeks, the obese mouse model was randomly divided into three groups: (1) DMV nucleus injection of control virus, followed by intraperitoneal injection of normal saline 4 weeks later, as the control group; (2) DMV nucleus injection of control virus, followed by intraperitoneal injection of puerarin solution 4 weeks later, as the puerarin group; (3) DMV nucleus injection of Gabrg2 shRNA virus, followed by intraperitoneal injection of puerarin solution 4 weeks later, as the Gγ2 blocking group; for the above three groups of animal models, body weight was recorded and fecal samples were collected before intraperitoneal injection of puerarin or normal saline as the initial baseline, which was counted as "Day 0". Starting from the first day, normal saline or puerarin solution was injected intraperitoneally once a day for 7 days, and the daily body weight changes were recorded. On the seventh day, the mice were sacrificed 2 hours after the injection of normal saline or puerarin, and blood, feces, small intestine, brain and other tissues were collected. Physiological indicators such as blood lipids and jejunal triglycerides were quantitatively measured, and the morphological results of the dorsal nucleus of the vagus nerve in the brainstem and the small intestine were directly detected by tissue sections.
[0095] Comparison of cfos staining results of DMV nuclei in the control group, puerarin group and Gγ2 blocking group ( Figure 7 B) and quantitative statistics ( Figure 7 C in Table 11); combined Figure 7 The quantitative statistical results of C in Figure 7 In B, the middle figure shows that the cfos staining signal of DMV neurons is inhibited by puerarin; Figure 7 B, right figure shows that tissue-specific knockdown of Gabrg2 can interfere with the inhibitory effect of puerarin on DMV neurons. The body weight curve after intraperitoneal injection of puerarin ( Figure 7 D in), measuring blood lipids ( Figure 7 E in Table 12) and triglycerides absorbed by the jejunum ( Figure 7 F in Table 13), indicating that DMV tissue-specific knockdown of Gabrg2 can block the inhibitory effect of puerarin on the vagus nerve, interfere with its inhibitory effect on small intestinal fat absorption, weight loss, and lipid reduction, indicating that GABA A The receptor γ2 subunit is the target of puerarin in the treatment of obesity.
[0096] Table 11 Percentage change of body weight curve (%)
[0097]
[0098] Table 12 Blood lipid levels (mM)
[0099]
[0100] Table 13 Jejunal triglyceride levels (μmol / mg / protein)
[0101]
[0102] In summary, GABA in the dorsal nucleus of the vagus nerve A The receptor α1 subunit and γ2 subunit are the drug targets of puerarin for weight loss and lipid-lowering effects. A The receptors can be used as drug targets in reducing blood lipids, treating obesity and improving metabolism. The present invention protects the dorsal nucleus of the vagus nerve and GABA A Application of receptors as drug targets for the treatment of obesity.
[0103] The present invention obtains puerarin derivatives by a chemical synthesis method (Lou Hongxiang, Sun Bin, Cui Changyi. Puerarin derivatives and preparation methods thereof and uses in preventing and treating cardiovascular and cerebrovascular diseases or diabetes and its complications [P].: CN201710464386.5, 20200228; Wang Lin, Zhang Shouguo, Peng Tao, Lv Qiujun. Synthesis and preliminary activity study of puerarin and its derivatives [A]. in: 2005 National Conference on Pharmaceutical Chemistry [C]. 2005.187-187; Zhang Bin. Synthesis study of puerarin derivatives and pyrazole compounds converted therefrom [D]. Shaanxi University of Science and Technology, 2016), and experimentally demonstrates the effects of each derivative in weight loss, lipid-lowering and obesity treatment applications, such as Figure 8 A- Figure 8 As shown in D and Tables 14 to 16, puerarin derivative-1 can significantly reduce the body weight of obese mice during intraperitoneal injection ( Figure 8 B), inhibiting the absorption of triglycerides in the small intestine ( Figure 8 D in), and effectively reduce blood lipid levels ( Figure 8 C in the figure). Puerarin derivative-2 and puerarin derivative-3 both showed the effects of inhibiting small intestinal fat absorption, lowering blood lipids and reducing body weight ( Figure 8 E- Figure 8 L in, and Tables 17 to 22).
[0104] Table 14 Puerarin derivative-1 group body weight change percentage (%)
[0105]
[0106] Table 15 Blood lipid levels of puerarin derivative-1 group (mM)
[0107]
[0108] Table 16 Jejunal triglyceride levels in the puerarin derivative-1 group (μmol / mg / protein)
[0109]
[0110] Table 17 Puerarin derivatives-2 group body weight change curve (%)
[0111]
[0112] Table 18 Blood lipid levels of puerarin derivatives-2 group (mM)
[0113]
[0114] Table 19 Jejunal triglyceride levels in the puerarin derivative-2 group (μmol / mg / protein)
[0115]
[0116] Table 20 Puerarin derivatives-3 group body weight change curve (%)
[0117]
[0118] Table 21 Puerarin derivatives - blood lipid levels in group 3 (mM)
[0119]
[0120] Table 22 Jejunal triglyceride levels in the puerarin derivative-3 group (μmol / mg / protein)
[0121]
[0122] In summary, GABA A The receptor can be activated through the "DMV nucleus-GABA A The puerarin (and its derivatives) disclosed in the present invention can inhibit the absorption of fat in the small intestine through the "receptor-vagus nerve-small intestinal nutrient absorption" pathway, thereby achieving the goals of lowering blood lipids, reducing weight and treating obesity. A Receptor agonists promote the opening of chloride ion channels, inhibit DMV nerve activity, and thus promote the body's goal of oil excretion and lipid reduction.
[0123] GABA A The receptor-regulated brain-gut axis mechanism can be used as a target for the preparation of obesity treatment drugs.
[0124] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. Use of puerarin and / or its derivatives in the preparation of drugs for inhibiting small intestinal fat absorption; The puerarin and / or puerarin derivative is GABA A Receptor agonists and / or allosteric agents; The drug inhibits the neural excitability of the dorsal nucleus of the vagus nerve; The puerarin derivative is puerarin derivative-1, puerarin derivative-2 or puerarin derivative-3; the chemical formulas of the puerarin derivative-1, puerarin derivative-2 and puerarin derivative-3 are as shown in Formula I to Formula III:
